For the next fiscal year, the consensus earnings estimate of $20.05 indicates a change of +12.8% from what Vertex is expected to report a year ago. Over the past month, the estimate has changed +1.5%.

For Vertex, the consensus sales estimate for the current quarter of $2.81 billion indicates a year-over-year change of +4.6%. For the current and next fiscal years, $11.85 billion and $12.96 ...

Vertex Pharmaceuticals reported disappointing Q1 revenue and earnings. The company also revealed it is temporarily pausing part of a phase 1/2 study of experimental cystic fibrosis drug VX-522 ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.